Global Neuromuscular Blocking Agent (NMBA) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Neuromuscular Blocking Agent (NMBA) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Report ID : 283283
Published On: Mar, 2022
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Neuromuscular Blocking Agent (NMBA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Neuromuscular Blocking Agent (NMBA) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Neuromuscular Blocking Agent (NMBA) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Depolarizing segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Neuromuscular Blocking Agent (NMBA) include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, and Abbott Laboratories, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Neuromuscular Blocking Agent (NMBA) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Depolarizing

Non-depolarizing

Market segment by Application can be divided into

Hospital

Clinic

Pharmacy

Others

The key market players for global Neuromuscular Blocking Agent (NMBA) market are listed below:

AbbVie

GlaxoSmithKline

Pfizer

Hengrui Pharmaceutical

Abbott Laboratories

Fresenius Kabi

Sandoz

Somerset Therapeutics

Guike Pharmaceutical

Shanghai Pharmaceuticals

Themis Medicare

Nanjing King-Friend

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Neuromuscular Blocking Agent (NMBA) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Neuromuscular Blocking Agent (NMBA), with price, sales, revenue and global market share of Neuromuscular Blocking Agent (NMBA) from 2019 to 2022.

Chapter 3, the Neuromuscular Blocking Agent (NMBA) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Neuromuscular Blocking Agent (NMBA) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuromuscular Blocking Agent (NMBA) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromuscular Blocking Agent (NMBA).

Chapter 13, 14, and 15, to describe Neuromuscular Blocking Agent (NMBA) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Neuromuscular Blocking Agent (NMBA) Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Depolarizing

1.2.3 Non-depolarizing

1.3 Market Analysis by Application

1.3.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Pharmacy

1.3.5 Others

1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size & Forecast

1.4.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume (2017-2028)

1.4.3 Global Neuromuscular Blocking Agent (NMBA) Price (2017-2028)

1.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity Analysis

1.5.1 Global Neuromuscular Blocking Agent (NMBA) Total Production Capacity (2017-2028)

1.5.2 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Neuromuscular Blocking Agent (NMBA) Market Drivers

1.6.2 Neuromuscular Blocking Agent (NMBA) Market Restraints

1.6.3 Neuromuscular Blocking Agent (NMBA) Trends Analysis

2 Manufacturers Profiles

2.1 AbbVie

2.1.1 AbbVie Details

2.1.2 AbbVie Major Business

2.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services

2.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 GlaxoSmithKline

2.2.1 GlaxoSmithKline Details

2.2.2 GlaxoSmithKline Major Business

2.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services

2.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Pfizer

2.3.1 Pfizer Details

2.3.2 Pfizer Major Business

2.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services

2.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Hengrui Pharmaceutical

2.4.1 Hengrui Pharmaceutical Details

2.4.2 Hengrui Pharmaceutical Major Business

2.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services

2.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Abbott Laboratories

2.5.1 Abbott Laboratories Details

2.5.2 Abbott Laboratories Major Business

2.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services

2.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 Fresenius Kabi

2.6.1 Fresenius Kabi Details

2.6.2 Fresenius Kabi Major Business

2.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services

2.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7 Sandoz

2.7.1 Sandoz Details

2.7.2 Sandoz Major Business

2.7.3 Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services

2.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8 Somerset Therapeutics

2.8.1 Somerset Therapeutics Details

2.8.2 Somerset Therapeutics Major Business

2.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services

2.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9 Guike Pharmaceutical

2.9.1 Guike Pharmaceutical Details

2.9.2 Guike Pharmaceutical Major Business

2.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services

2.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10 Shanghai Pharmaceuticals

2.10.1 Shanghai Pharmaceuticals Details

2.10.2 Shanghai Pharmaceuticals Major Business

2.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services

2.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11 Themis Medicare

2.11.1 Themis Medicare Details

2.11.2 Themis Medicare Major Business

2.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services

2.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12 Nanjing King-Friend

2.12.1 Nanjing King-Friend Details

2.12.2 Nanjing King-Friend Major Business

2.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services

2.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Neuromuscular Blocking Agent (NMBA) Breakdown Data by Manufacturer

3.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Neuromuscular Blocking Agent (NMBA)

3.4 Market Concentration Rate

3.4.1 Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share in 2021

3.4.2 Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share in 2021

3.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Neuromuscular Blocking Agent (NMBA) Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Region

4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2017-2028)

4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2028)

4.2 North America Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028)

4.3 Europe Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028)

4.4 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028)

4.5 South America Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028)

4.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Type (2017-2028)

5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2017-2028)

5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Application (2017-2028)

6.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2017-2028)

6.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2028)

7.2 North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2028)

7.3 North America Neuromuscular Blocking Agent (NMBA) Market Size by Country

7.3.1 North America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2017-2028)

7.3.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2028)

8.2 Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2028)

8.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size by Country

8.3.1 Europe Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2017-2028)

8.3.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2028)

9.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2028)

9.3 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Size by Region

9.3.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2028)

10.2 South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2028)

10.3 South America Neuromuscular Blocking Agent (NMBA) Market Size by Country

10.3.1 South America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2017-2028)

10.3.2 South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2028)

11.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2028)

11.3 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size by Country

11.3.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Neuromuscular Blocking Agent (NMBA) and Key Manufacturers

12.2 Manufacturing Costs Percentage of Neuromuscular Blocking Agent (NMBA)

12.3 Neuromuscular Blocking Agent (NMBA) Production Process

12.4 Neuromuscular Blocking Agent (NMBA) Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Neuromuscular Blocking Agent (NMBA) Typical Distributors

13.3 Neuromuscular Blocking Agent (NMBA) Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. AbbVie Basic Information, Manufacturing Base and Competitors

Table 4. AbbVie Major Business

Table 5. AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services

Table 6. AbbVie Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table 8. GlaxoSmithKline Major Business

Table 9. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services

Table 10. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. Pfizer Basic Information, Manufacturing Base and Competitors

Table 12. Pfizer Major Business

Table 13. Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services

Table 14. Pfizer Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Hengrui Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 16. Hengrui Pharmaceutical Major Business

Table 17. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services

Table 18. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Abbott Laboratories Basic Information, Manufacturing Base and Competitors

Table 20. Abbott Laboratories Major Business

Table 21. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services

Table 22. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Fresenius Kabi Basic Information, Manufacturing Base and Competitors

Table 24. Fresenius Kabi Major Business

Table 25. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services

Table 26. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Sandoz Basic Information, Manufacturing Base and Competitors

Table 28. Sandoz Major Business

Table 29. Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services

Table 30. Sandoz Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 31. Somerset Therapeutics Basic Information, Manufacturing Base and Competitors

Table 32. Somerset Therapeutics Major Business

Table 33. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services

Table 34. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 35. Guike Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 36. Guike Pharmaceutical Major Business

Table 37. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services

Table 38. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 39. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 40. Shanghai Pharmaceuticals Major Business

Table 41. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services

Table 42. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 43. Themis Medicare Basic Information, Manufacturing Base and Competitors

Table 44. Themis Medicare Major Business

Table 45. Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services

Table 46. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 47. Nanjing King-Friend Basic Information, Manufacturing Base and Competitors

Table 48. Nanjing King-Friend Major Business

Table 49. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services

Table 50. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 51. Global Neuromuscular Blocking Agent (NMBA) Sales by Manufacturer (2019, 2020, 2021, and 2022) & (MT)

Table 52. Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 53. Market Position of Manufacturers in Neuromuscular Blocking Agent (NMBA), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 54. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company, (MT): 2020 VS 2021

Table 55. Head Office and Neuromuscular Blocking Agent (NMBA) Production Site of Key Manufacturer

Table 56. Neuromuscular Blocking Agent (NMBA) New Entrant and Capacity Expansion Plans

Table 57. Neuromuscular Blocking Agent (NMBA) Mergers & Acquisitions in the Past Five Years

Table 58. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2017-2022) & (MT)

Table 59. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2023-2028) & (MT)

Table 60. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2022) & (USD Million)

Table 61. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2023-2028) & (USD Million)

Table 62. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 63. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 64. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2017-2022) & (USD Million)

Table 65. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2023-2028) & (USD Million)

Table 66. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2017-2022) & (USD/MT)

Table 67. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2023-2028) & (USD/MT)

Table 68. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 69. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 70. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2017-2022) & (USD Million)

Table 71. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2023-2028) & (USD Million)

Table 72. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2017-2022) & (USD/MT)

Table 73. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2023-2028) & (USD/MT)

Table 74. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)

Table 75. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2023-2028) & (MT)

Table 76. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (USD Million)

Table 77. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2023-2028) & (USD Million)

Table 78. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 79. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 80. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 81. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 82. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)

Table 83. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2023-2028) & (MT)

Table 84. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (USD Million)

Table 85. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2023-2028) & (USD Million)

Table 86. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 87. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 88. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 89. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 90. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2017-2022) & (MT)

Table 91. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2023-2028) & (MT)

Table 92. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2022) & (USD Million)

Table 93. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2023-2028) & (USD Million)

Table 94. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 95. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 96. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 97. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 98. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)

Table 99. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2023-2028) & (MT)

Table 100. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (USD Million)

Table 101. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2023-2028) & (USD Million)

Table 102. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 103. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 104. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 105. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 106. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Region (2017-2022) & (MT)

Table 107. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Region (2023-2028) & (MT)

Table 108. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2022) & (USD Million)

Table 109. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Region (2023-2028) & (USD Million)

Table 110. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)

Table 111. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2023-2028) & (MT)

Table 112. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2017-2022) & (MT)

Table 113. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2023-2028) & (MT)

Table 114. Neuromuscular Blocking Agent (NMBA) Raw Material

Table 115. Key Manufacturers of Neuromuscular Blocking Agent (NMBA) Raw Materials

Table 116. Direct Channel Pros & Cons

Table 117. Indirect Channel Pros & Cons

Table 118. Neuromuscular Blocking Agent (NMBA) Typical Distributors

Table 119. Neuromuscular Blocking Agent (NMBA) Typical Customers

List of Figures

Figure 1. Neuromuscular Blocking Agent (NMBA) Picture

Figure 2. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type in 2021

Figure 3. Depolarizing

Figure 4. Non-depolarizing

Figure 5. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application in 2021

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Pharmacy

Figure 9. Others

Figure 10. Global Neuromuscular Blocking Agent (NMBA) Revenue, (USD Million) & (MT): 2017 & 2021 & 2028

Figure 11. Global Neuromuscular Blocking Agent (NMBA) Revenue and Forecast (2017-2028) & (USD Million)

Figure 12. Global Neuromuscular Blocking Agent (NMBA) Sales (2017-2028) & (MT)

Figure 13. Global Neuromuscular Blocking Agent (NMBA) Price (2017-2028) & (USD/MT)

Figure 14. Global Neuromuscular Blocking Agent (NMBA) Production Capacity (2017-2028) & (MT)

Figure 15. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region: 2022 VS 2028

Figure 16. Neuromuscular Blocking Agent (NMBA) Market Drivers

Figure 17. Neuromuscular Blocking Agent (NMBA) Market Restraints

Figure 18. Neuromuscular Blocking Agent (NMBA) Market Trends

Figure 19. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturer in 2021

Figure 20. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturer in 2021

Figure 21. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 22. Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2021

Figure 23. Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2021

Figure 24. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2028)

Figure 25. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2028)

Figure 26. North America Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028) & (USD Million)

Figure 27. Europe Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028) & (USD Million)

Figure 28. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028) & (USD Million)

Figure 29. South America Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028) & (USD Million)

Figure 30. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue (2017-2028) & (USD Million)

Figure 31. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2028)

Figure 32. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2017-2028)

Figure 33. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2017-2028) & (USD/MT)

Figure 34. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 35. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2017-2028)

Figure 36. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2017-2028) & (USD/MT)

Figure 37. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2028)

Figure 38. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 39. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2028)

Figure 40. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2028)

Figure 41. United States Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Canada Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Mexico Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2028)

Figure 45. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 46. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2028)

Figure 47. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2028)

Figure 48. Germany Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. France Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. United Kingdom Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Russia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Italy Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2028)

Figure 54. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 55. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2028)

Figure 56. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2028)

Figure 57. China Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Japan Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Korea Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. India Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Australia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2028)

Figure 64. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 65. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2028)

Figure 66. South America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2028)

Figure 67. Brazil Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Argentina Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2028)

Figure 70. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2028)

Figure 71. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2028)

Figure 72. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2028)

Figure 73. Turkey Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Egypt Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. South Africa Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Manufacturing Cost Structure Analysis of Neuromuscular Blocking Agent (NMBA) in 2021

Figure 78. Manufacturing Process Analysis of Neuromuscular Blocking Agent (NMBA)

Figure 79. Neuromuscular Blocking Agent (NMBA) Industrial Chain

Figure 80. Sales Channel: Direct Channel vs Indirect Channel

Figure 81. Methodology

Figure 82. Research Process and Data Source

License Type

Quick Contact

Our Clients

Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz